|
목적 : To evaluate the short-term efficacy of intravitreal ranibizumab(IVR) injection in diabetic
macular edema (DME) unresponsive to previous intravitreal bevacizumab(IVB).
방법 : The medical records of 41 DME patients who showed poor response to at least three monthly IVB and underwent one to three IVR were reviewed. Each patient received a single IVR and followed up at 1 month. Anatomic responders, defined as patients exhibiting a dry macula or a decrease in CMT of > 50 µm compared with baseline after initial IVR, were followed up monthly and given IVR on an as-needed basis until 3 months.
결과 : At 1 month, the mean central macular thickness(CMT) decreased from 431μm to 349μm (P<.001), and mean BCVA improved from 20/54 to 20/48 (P=.062). Twenty-six patients(63.4%) were classified as anatomical responders. At 3 months, improvement of CMT was maintained (439μm to 320μm, P<.001), and mean BCVA improved significantly compared with baseline in these patients. (20/60 to 20/53, P=.033) Complete fluid absorption were achieved in 7 eyes (17.1%) at least once during 3 months follow-up period, however, recurrent exudation were noted in 6 eyes at the next month.
결론 : IVR may present an alternative option in the treatment of DME nonresponsive to consecutive IVBs over the short-term. In this study, IVR was found to be more effective in patients having DME for a shorter duration of time
|